ZINC GLUCONATE ( DrugBank: Zinc, Zinc gluconate )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 171 | ウィルソン病 | 4 |
171. ウィルソン病
臨床試験数 : 79 / 薬物数 : 77 - (DrugBank : 17) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 30
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100053629 | 2021-12-12 | 2021-11-26 | A multicenter, randomized controlled, double-blind and double simulated clinical evaluation of gandouling tablet in the treatment of Wilson's disease | A multicenter, randomized controlled, double-blind and double simulated clinical evaluation of gandouling tablet in the treatment of patients with hepatolenticular degeneration | Wilson's disease | A group:Gandouling tablet + zinc gluconate simulator;B group:Zinc gluconate + gandouling tablet simulator; | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | NULL | Pending | 15 | Both | A group:100;B group:100; | China | ||
| 2 | ITMCTR2100005333 | 2021-12-12 | 2021-11-26 | A multicenter, randomized controlled, double-blind and double simulated clinical evaluation of gandouling tablet in the treatment of Wilson's disease | A multicenter, randomized controlled, double-blind and double simulated clinical evaluation of gandouling tablet in the treatment of patients with hepatolenticular degeneration | Wilson's diasease | 2:Zinc gluconate;1:Gandouling; | The First Affiliated Hospital of Anhui University of traditional Chinese Medicine | NULL | Pending | 15 | 85 | Both | 2:100;1:100; | Phase 1 | China |
| 3 | EUCTR2019-000905-57-DK (EUCTR) | 17/04/2019 | 14/03/2019 | Efficacy of zinc on copper uptake in the body depending on zinc type and dose regimen measured with 64CuCl2 PET/CT-scan | Efficacy of zinc on human gut copper uptake depending on zinc type and dose regimen quantified with 64CuCl2 PET/CT-scan | Healthy volunteers (Wilson's disease) MedDRA version: 20.0;Level: LLT;Classification code 10047988;Term: Wilson's disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Wilzin INN or Proposed INN: Zinc acetate Trade Name: Zink Natur-Drogeriet INN or Proposed INN: Zinc gluconate Other descriptive name: ZINC GLUCONATE Product Name: 64CuCl2 INN or Proposed INN: 64CuCl2 Other descriptive name: COPPER (64CU) CHLORIDE | The Department of Hepatology and Gastroenterology, Aarhus University Hospital | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 4 | Denmark | ||
| 4 | NCT03957720 (ClinicalTrials.gov) | March 15, 2019 | 8/4/2019 | The Individual Therapy for Patients With Wilson's Disease | The Individual Therapy for Patients With Wilson's Disease | Wilson's Disease | Drug: DMPS;Drug: Penicillamine;Drug: DMSA;Drug: Zinc gluconate | Second Affiliated Hospital, School of Medicine, Zhejiang University | NULL | Recruiting | N/A | N/A | All | 400 | Early Phase 1 | China |